Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy (TACEHBV)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2010 by Fudan University.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Fudan University
ClinicalTrials.gov Identifier:
NCT01102335
First received: April 8, 2010
Last updated: April 12, 2010
Last verified: April 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2012
  Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)